News desk
News Desk: Compounding Regulation and Enforcement, 2025-2026
Dated regulatory and enforcement events in compounding, 2025 to 2026, each traceable to an official record.
16 dated events covering the end of shortage-based compounding, the litigation that followed, the April 2026 bulks-list proposal, and facility-level FDA inspection and enforcement records. 5 events in 2026 and 11 in 2025, each resolving to an FDA order, an inspection record, or a court decision.
Key findings
- 16 dated events: 5 in 2026, 11 in 2025.
- 8 regulatory, 7 enforcement, 1 pricing.
- Enforcement entries are reported at facility level — a record at one site does not describe another.
- A Form 483 lists observations; an open action status records no decision either way.
- Entries appear only when they resolve to a dated official record.
| Events | 16 |
|---|---|
| 2026 | 5 |
| 2025 | 11 |
| Enforcement entries | 7 |
| Snapshot | 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
Every dated event, most recent first
Timeline data as a table
| 2026-06-29 | FDA comment docket closes on the 503B bulks list proposal |
|---|---|
| 2026-05-12 | Warning letter issued to a Fagron Sterile Services facility |
| 2026-05-04 | QuVa Pharma Sugar Land inspected |
| 2026-04-30 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list |
| 2026-02-27 | Regulatory meeting held over Fagron Wichita inspection |
| 2025-11-14 | Empower Pharma Houston inspected |
| 2025-11-05 | Fagron Canton inspected |
| 2025-11-01 | NovoCare cuts Wegovy pen self-pay pricing |
| 2025-08-08 | Three outsourcing facilities inspected on the same date |
| 2025-07-16 | 93 outsourcing facilities on the FDA register |
| 2025-04-24 | Court denies second preliminary injunction in OFA v. FDA |
| 2025-04-04 | QuVa Pharma Bloomsbury inspected |
| 2025-03-19 | 503B enforcement discretion for tirzepatide ends |
| 2025-03-05 | Court denies preliminary injunction in OFA v. FDA |
| 2025-02-21 | FDA removes semaglutide injection from the shortage list |
| 2025-02-18 | 503A enforcement discretion for tirzepatide ends |
2026 — 5 events
FDA comment docket closes on the 503B bulks list proposal
The public comment window on excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list closed. FDA will weigh submissions before a final determination.
Why it matters. If finalised, large-scale outsourcing facilities lose any pathway to compound these molecules from bulk — even if a future shortage were declared.
Warning letter issued to a Fagron Sterile Services facility
FDA issued a warning letter to the Fresenius Kabi Compounding LLC dba Fagron Sterile Services facility in Canton, Massachusetts, following a 5 November 2025 inspection that produced Form 483 observations.
Why it matters. A warning letter is the agency's stated position on specific violations, scoped to its findings and to that facility. The Wichita facility under the same trading name has a separate record.
QuVa Pharma Sugar Land inspected
FDA inspected the QuVa Pharma facility in Sugar Land, Texas. No Form 483 was recorded and the action status is open.
Why it matters. Registration and inspection are facility-specific. QuVa's Bloomsbury, New Jersey site carries a separate record from April 2025.
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list
FDA announced a proposal to exclude all three from the bulk drug substances list for outsourcing facilities, finding no clinical need to compound them from bulk.
Why it matters. This would close the bulk route permanently rather than until the next shortage — a structural change rather than a temporary restriction.
Regulatory meeting held over Fagron Wichita inspection
A regulatory meeting was held concerning the Fagron Compounding Services facility in Wichita, Kansas, following an 8 August 2025 inspection with Form 483 observations.
Why it matters. A regulatory meeting sits between an observation and a formal action. It is not itself a finding of violation.
2025 — 11 events
Empower Pharma Houston inspected
FDA inspected the Empower Pharma facility in Houston, Texas. Form 483 observations were issued and the action status remains open.
Why it matters. Open means FDA has not determined whether further action will be taken — the absence of a decision, not the presence of a finding.
Fagron Canton inspected
FDA inspected the Fresenius Kabi Compounding LLC dba Fagron Sterile Services facility in Canton, Massachusetts. Form 483 observations were issued.
Why it matters. This inspection preceded the warning letter issued to the same facility on 12 May 2026.
NovoCare cuts Wegovy pen self-pay pricing
Novo Nordisk reduced NovoCare Pharmacy self-pay pricing for Wegovy maintenance doses from $499 to $349 per month.
Why it matters. Brand self-pay pricing fell sharply through late 2025, narrowing the gap that had made compounded preparations attractive.
Three outsourcing facilities inspected on the same date
FDA inspected AnazaoHealth in Las Vegas, Olympia Pharmaceuticals in Orlando, and Fagron Compounding Services in Wichita. All three received Form 483 observations.
Why it matters. Of 55 inspected 503B facilities, 53 had received a Form 483 as of July 2025 — observations are close to universal, so content and outcome carry the information.
93 outsourcing facilities on the FDA register
FDA's registered outsourcing facility list stood at 93 facilities. Of 48 newly registered since June 2021, 39 had never been inspected.
Why it matters. A facility may register, begin compounding and ship nationwide before any inspection — unlike a conventional manufacturer, which must demonstrate capability first.
Court denies second preliminary injunction in OFA v. FDA
The district court denied a further preliminary injunction sought by the Outsourcing Facilities Association against FDA's shortage resolution.
Why it matters. This effectively closed the litigation route against the determination that ended shortage-based compounding.
QuVa Pharma Bloomsbury inspected
FDA inspected the QuVa Pharma facility in Bloomsbury, New Jersey. Form 483 observations were issued and the action status remains open.
Why it matters. Facility-specific: the Sugar Land site was inspected separately in May 2026 with a different outcome.
503B enforcement discretion for tirzepatide ends
Registered outsourcing facilities were required to stop compounding tirzepatide copies.
Why it matters. The 503A deadline had passed a month earlier, so pharmacies and outsourcing facilities operated under different rules through February and March.
Court denies preliminary injunction in OFA v. FDA
The district court denied the Outsourcing Facilities Association's first preliminary injunction against FDA's tirzepatide shortage resolution.
Why it matters. The industry challenge failed at the first hurdle, leaving the enforcement deadlines intact.
FDA removes semaglutide injection from the shortage list
A declaratory order removed semaglutide injection products from the drug shortage list.
Why it matters. This closed the shortage exception for semaglutide, as the December order had for tirzepatide.
503A enforcement discretion for tirzepatide ends
State-licensed pharmacies were required to stop compounding tirzepatide copies.
Why it matters. The first hard deadline of the wind-down, and the point at which the largest part of the market became unlawful.
How events are selected
An entry appears here only when it resolves to a dated official record: an FDA order or announcement, an inspection or enforcement record published by the agency, or a court decision. Media reports, consumer allegations and provider announcements do not qualify on their own.
Enforcement entries carry the same framing rules applied everywhere on this platform. A Form 483 lists observations, not findings. An action status of 'Open' records the absence of a decision. A warning letter is scoped to the violations it states and to the facility it names.
What this means
- Every entry has a date and a source category.
- Enforcement entries are reported at facility level, not company level.
- Observations, actions and resolutions are distinguished throughout.
What this does not mean
- That any entity named is compliant or non-compliant.
- That an open action status indicates wrongdoing.
- That this list is exhaustive — it covers what this platform has verified.
- Covers events verified up to 2026-07-23. Not a real-time feed.
- Warning-letter closeout status is not established for entries here.
- Recall history is not covered by the FDA table these entries draw on.
- Absence of an event does not mean none occurred.
Frequently asked questions
What qualifies as news here?
An event that resolves to a dated official record — an FDA order or announcement, a published inspection or enforcement record, or a court decision.
Does a Form 483 mean a violation was found?
No. It lists an investigator's observations at the close of an inspection. The outcome, not the observation, determines regulatory standing.
What does an open action status mean?
That FDA has not determined whether further action will be taken. It records the absence of a decision, not a finding.
Is this list complete?
It covers events this platform has verified. Absence of an entry does not mean none occurred.
Sources
- FDA — Registered Outsourcing Facilities
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.